I+D

I+D

I+D (2)

I+D (2)

I+D (3)

I+D (3)

I+D (4)

I+D (4)

R&D Division

Development of Sustainable processes.
New products for rare and poverty-related diseases.
Investigación y Research and Development of new Active Pharmaceutical Ingredients.


At our newly constructed R&D plant, we assure the best drug research and development, both with companies in the PRAXIS Group, and collaborations with other companies and R&D institutions worldwide.

Our capabilities
Development of biotechnological or highly specialised products for the hospital market.

  • Development of Micro- and Nanoformulations of Innovative Medicines
  • Development and Scaling of Innovative and sustainable solutions for pharmaceutical processes.
  • Product research and development in three main lines of research: Biotechnological, Synthetic Peptides and products and processes against Rare and poverty-related diseases.
  • Development of Treatments for poorly healing wounds.
  • Identification of the environmental impact giving rise to the production of bio-based drugs and nanotechnology, including environmental and energy efficient equipment for the production of pilot and industrial batches.
  • Flexible team and highly qualified, experienced researchers.

Lines of research

  • Biotechnology R&D for Regenerative Therapy
  • R&D in Synthetic Peptides
  • R&D in Micro and Nanoencapsulation of Drugs

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continúa navegando, consideramos que acepta su uso. Puede obtener más información, o bien conocer cómo cambiar la configuración, en nuestro enlace Políticas de Seguridad. We use our own cookies and third-party cookies to improve our services and show related advertising to your preferences by analyzing their browsing habits. If you continue to browse, consider accepting its use. You can get more information, or how to change the settings in our Política de privacidad.